Brandon Carney

- CATX's VMT-α-NET, a targeted alpha-particle therapy for advanced SSTR2+ neuroendocrine tumors (NETs), demonstrated an **Objective Response Rate (ORR) of 44%** (7 of 16 patients with SSTR2+ tumors) at a median follow-up of **41 weeks** in its Phase 1/2 study.  **[0000728387_2191463:6]** **[0000728387_2191463:9]** **[0000728387_2191463:18]** 
- The treatment was **well-tolerated**, with no grade 4 or 5 adverse events or treatment-related discontinuations reported among the 55 patients treated as of September 12, 2025.  **[0000728387_2191463:6]** **[0000728387_2191463:9]** **[0000728387_2191463:18]** 
- This interim data suggests potential for **greater efficacy compared to Lutathera** (13% ORR) and supports a potential registration study.  **[0000728387_2191463:6]** **[0000728387_2191463:7]** **[0000728387_2191463:19]** 
- As of **September 30, 2025**, CATX reported **~$174 million** in cash, cash equivalents, and short-term investments, providing sufficient funding into **late 2026**.  **[0000728387_2191463:20]** 
- Upcoming data milestones for VMT-α-NET include anti-tumor activity data from nearly all Cohort 2 patients in **early 2026** and initial anti-tumor activity data from the first 8 Cohort 3 patients in **mid-2026**.  **[0000728387_2191463:20]**

CATX Provides Positive Clinical Update for VMT-α-NET and Financial Outlook

- Perspective Therapeutics, Inc. (CATX) presented updated interim results for its **[212Pb]VMT-α-NET** Phase 1/2a clinical trial at the ESMO Congress 2025 on **October 20, 2025**.  **[728387_0001193125-25-242912_catx-ex99_1.htm:0]** **[728387_0001193125-25-242912_catx-20251020.htm:1]** 
- The drug candidate demonstrated continued **tolerability** and an **Objective Response Rate of 44%** (7 of 16 patients) in Cohort 2 (patients with SSTR2 expression in all tumors) at a median follow-up of **41 weeks**.  **[728387_0001193125-25-242912_catx-ex99_1.htm:0]** **[728387_0001193125-25-242912_catx-ex99_1.htm:1]** 
- As of **September 12, 2025**, **14 out of 16 patients** in this Cohort 2 group remained **free from progression and on study**.  **[728387_0001193125-25-242912_catx-ex99_1.htm:0]** **[728387_0001193125-25-242912_catx-ex99_1.htm:1]** 
- The company's preliminary cash, cash equivalents, and short-term investments totaled approximately **$174.1 million** as of **September 30, 2025**, projected to fund operations into **late 2026**.  **[728387_0001193125-25-242912_catx-ex99_1.htm:1]**

Perspective Therapeutics (CATX)